Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)

NCT00054899 is registered in ClinicalTrials.gov with Epimmune as lead sponsor.

NCT NCT00054899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00054899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Epimmune
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2003
Completion date
Not reported
Enrollment
18
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung neoplasm